Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-10-07
2008-11-04
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S009100, C514S013800, C530S317000, C530S326000, C530S328000, C530S387200, C424S131100
Reexamination Certificate
active
07446095
ABSTRACT:
The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the active site contain two sequences, Arg-Gly-Asp and Asp-X-X-Asp, wherein X means any amino acid. These sequences are needed in the same molecule for causing a wide range of biological activities. The peptides can be utilized to suppress apoptotic pathways by inhibiting the cytochrome c-mediated caspase activation. Thus, the peptides can be used to inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorders and immunodeficiency syndrome induced by viral infection, or to diminish side cytotoxic effects after chemotherapy and radiation therapy.
REFERENCES:
patent: 0353814 (1990-02-01), None
patent: WO96/22787 (1996-08-01), None
patent: WO98/10787 (1997-09-01), None
patent: WO98/35981 (1998-08-01), None
patent: WO01/15709 (2001-03-01), None
patent: WO03/007978 (2003-01-01), None
Rudinger J, Characteriistics of the amino acids as components of a peptide hormone sequence, Peptide Hormones, JA Parsons, Edition, 1976, 1-7.
Designing Custom Peptides from SIGMA, Dec. 16, 2004 web access, 1-2.
Berendsen HJC, A Glimpse of the Holy Grail?, Science, 1998, 282: 642-643.
Voet D and Voet JG, Biochemistry, 2ndEdition, John Wiley & Sons, Inc., 1995, 235-241.
Bennet et al. 2001: A petide derived from alpha fetoprotein prevents . . . PNAS vol. 99; No. 4. 2211-2215.
Dudich I. et al 1999. Isolation and Structural and Functional Characterization . . . Biochemistry 38:10406-10414.
Buckley et al. 1999. RGD peptides induce apoptosis by direct caspase . . . Nature vol. 397 p. 534-539.
Bratton S. B et al. 2001. Recruitment, activation and retention of . . . The EMBO Journal 20. No. 5. pp. 998-1009.
Cohen G. M. 1997. Caspase: the executionres of apoptosis. Biochem J. 326: 1-16.
Dudich E. et al. 1999 Alpha Fetprotein causes apoptosis in tumor . . . Eur. J. Biochem. 266, 750-761.
Semenkova L. et al. 2003. Alpha Fetoproein positively regulates cytochrome Eur. J. Biochem 270: 4388-4399.
Maccoll et al. 2001. Interrelationships among biological activity, disulfide . . . Biochimica et Biophyscia Acta 1528: 127-134.
Morinaga T. et al. 1983. Primary structures of human alpha fetoprotein . . . Proc. Natl. Acad. Sci USA vol. 80 pp. 4604-4608.
Nagata S. 1997. Apoptosis by Death Factor. Cell 88:355-365.
Pasqualini, R. et al. 1995. A peptide isolated form phage display . . . The Journal of Cell Biology. vol. 130: 5 pp. 1189-1196.
Dudich Elena Ivanovna
Dudich Igor Vyacheslavovitch
Korpela Timo Kalevi
Semenkova Lidia Nikolaevna
Tatulov Edvward Borisovitch
Dodds John
Dodds and Associates
Gupta Anish
Ha Julie
Somersalo Susanne
LandOfFree
Peptides modulating caspase activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides modulating caspase activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides modulating caspase activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4023065